Finvest
HUM Healthcare · Medicare · Managed care · Healthcare services · Thesis updated July 12, 2026

Humana’s margin repair looks painful

01 Running thesis

A fix that may shrink the base

Humana’s near-term setup is weak. The company is still a large Medicare insurer, but the main issue is simple: medical claims are eating too much of the premium dollars it collects. In Q1 2026, the Insurance benefit ratio was 89.4%. That means 89.4 cents of each premium dollar went to member benefits before normal operating costs.

The bear case got stronger because Humana is adding members while margins are falling. Individual Medicare Advantage membership rose by 1,177,500 members from March 31, 2025 to March 31, 2026. Yet management said new members, on average, have a higher benefit ratio than retained members. Growth that hurts profit is not the kind investors want.

The bull case is now mostly a 2027 story. On the Q1 2026 call, management signaled that benefit cuts are likely in 2027 Medicare Advantage bids. If Humana cuts benefits enough, keeps enough members, and moves margins back toward its target over time, the stock can recover. That is a narrow path because rivals can use richer benefits to win members away.

CenterWell does not fix the problem today. The segment’s Q1 2026 operating income fell 26.3%, and its operating cost ratio rose to 94.5%. Humana says the v28 risk model change, integration costs, and business mix are pressuring margins. That leaves both major segments under pressure at the same time.

Apr 2026Q1 2026 confirmed margin pressure. The Insurance benefit ratio reached 89.4%, Q2 was guided above 91%, and management pointed to likely 2027 benefit cuts as the repair tool.
Feb 2026The 2025 Form 10-K showed the prior strategy was not working well enough. Individual Medicare Advantage membership fell 7.3% in 2025, while the consolidated benefit ratio still worsened.
Nov 2025Q3 2025 weakened the thesis again. Medicare Advantage membership losses accelerated and the consolidated benefit ratio rose to 91.1%.
Jul 2025Q2 2025 reversed the early margin hope. The benefit ratio worsened while Individual Medicare Advantage membership was still falling.
Apr 2025Q1 2025 briefly supported the turnaround case. Humana shed unprofitable members and the consolidated benefit ratio improved to 87.0%.
Feb 2025The 2024 Form 10-K raised the Star Ratings risk. Humana said only about 25% of Medicare Advantage members were in 4-star or higher plans for 2025, down from 94% based on 2024 ratings.
Oct 2024Q3 2024 showed high medical cost trends and a major Star Ratings problem. That created a clear risk to 2026 bonus payments.
02 Business model

Premiums in, claims out

Humana makes most of its money by selling health plans. The biggest pool is Medicare Advantage, a private plan option for people on Medicare. Humana gets premiums, including payments tied to government programs, and then pays doctors, hospitals, drug costs, and member benefits.

The key profit lever is the benefit ratio. A lower ratio means Humana keeps more premium dollars after paying medical costs. A higher ratio means claims are taking more of the money. In Q1 2026, the consolidated benefit ratio rose from 87.0% to 89.4% year over year, which is why the thesis is negative.

CenterWell is the services side. It includes pharmacy solutions, primary care, and home solutions. It serves Humana members and outside payors, but it is tied closely to the insurance book. The idea is to manage care better and lower costs over time.

That model breaks when funding, plan pricing, member mix, and medical use do not line up. Star Ratings pressure is also important because lower-rated Medicare Advantage plans can receive lower quality bonus payments from CMS. Humana’s filing says about 25% of its Medicare Advantage members were in plans rated 4-star or higher for 2025, down from 94% based on 2024 Star Ratings.

03 Product portfolio

Medicare first, services second

Cash cow

Individual Medicare Advantage

This is Humana’s core product. It is also the main problem right now because Q1 2026 growth came with a higher benefit ratio for new members.

Steady

Group Medicare Advantage

These plans are sold through group accounts. Q1 2026 membership rose 27.3%, helped by the 2026 selling season.

Steady

Medicare stand-alone PDP

These are prescription drug plans for Medicare members. Q1 2026 membership rose 58.7%, but PDP and Part D economics are sensitive to federal benefit design.

Steady

Medicaid, state-based contracts, and military services

These government-linked lines add scale and contract revenue. They can carry different margin profiles than Medicare Advantage.

Steady

CenterWell pharmacy solutions

This business fills and manages prescriptions. In Q1 2026, higher specialty pharmacy volume helped revenue but also pressured the cost ratio.

Growth engine

CenterWell primary care and home solutions

These services are meant to improve care and lower medical use over time. Recent acquisitions, including MaxHealth, add growth but also bring integration costs.

04 Business segments

Two segments, one big driver

Insurance96%modest
CenterWell4%growing fast

The mix uses Q1 2026 external segment revenue from Humana’s Form 10-Q. Insurance is almost all of the external revenue base, while CenterWell is larger internally because it also sells services to Humana’s Insurance segment.

05 Risk factors

What could go wrong

Medical costs outrun pricing

High impact · High odds

Humana’s main risk is that claims keep rising faster than premiums and plan changes. The Q1 2026 Insurance benefit ratio was 89.4%, and management projected Q2 could be above 91%. If that happens, profit pressure gets worse before any 2027 fix can help.

We watchQ2 2026 Insurance benefit ratio and any change to full-year adjusted EPS guidance.

2027 benefit cuts backfire

High impact · Medium odds

Management has signaled that 2027 Medicare Advantage benefit cuts are likely. That could repair margins, but members may leave if rival plans offer better benefits. The risk is a smaller and weaker revenue base, not just a one-year reset.

We watch2027 bid commentary, Annual Election Period enrollment, and Individual MA retention.

Star Ratings bonus hit

High impact · High odds

Humana disclosed that about 25% of Medicare Advantage members were in plans rated 4-star or higher for 2025, compared with 94% based on 2024 Star Ratings. The company says this will hurt 2026 quality bonus payments unless its legal challenge or other actions help. Lower bonus dollars make pricing and benefits harder.

We watchCMS Star Ratings updates, the lawsuit outcome, and any 2026 bonus payment commentary.

CenterWell margin reset

Medium impact · High odds

CenterWell is supposed to be Humana’s services growth engine, but Q1 2026 operating income fell 26.3%. The segment’s operating cost ratio rose to 94.5%, with pressure from the v28 risk model, specialty pharmacy mix, and acquisition costs. If mitigation work fails, CenterWell may be less valuable than investors hoped.

We watchCenterWell operating cost ratio, operating income, and updates on v28 mitigation activities.

Reserves prove too low

Medium impact · Medium odds

Humana’s results depend on estimating medical claims that have happened but are not fully paid yet. Q1 2026 operating cash flow benefited from an increase in the IBNR balance. If cost trends are worse than reserved, later quarters can take the hit.

We watchPrior-period medical claims reserve development and management comments on IBNR adequacy.
06 Quick answers

In one breath

What does Humana do?

Humana sells health insurance, mainly Medicare Advantage plans, and runs CenterWell healthcare services. CenterWell includes pharmacy, primary care, and home solutions.

Why is Humana under pressure?

Medical costs are taking a larger share of premium revenue. In Q1 2026, the Insurance benefit ratio was 89.4%, and management said Q2 could move above 91%.

What could improve the Humana story?

The clearest path is 2027 Medicare Advantage repricing and benefit cuts. The hard part is doing that without losing too many members to competitors.